Press Releases Items Per Page 102550 Year None202020192018 09-24-2020 Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance 09-09-2020 Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference 08-12-2020 Akero Therapeutics Reports Second Quarter 2020 Financial Results 07-21-2020 Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate 07-10-2020 Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 07-07-2020 Akero Therapeutics Announces Pricing of Public Offering of Common Stock 07-06-2020 Akero Therapeutics Announces Proposed Public Offering of Common Stock 06-30-2020 Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients 06-29-2020 Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001 06-17-2020 Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
09-24-2020 Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance
09-09-2020 Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference
07-21-2020 Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate
07-10-2020 Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
06-30-2020 Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
